Seeking Alpha

Celgene (CELG) -10.2% after EU regulators request more data about widening authorization of the...

Celgene (CELG) -10.2% after EU regulators request more data about widening authorization of the firm's multiple myeloma treatment Revlimid to treat newly diagnosed patients and as a maintenance therapy. Celgene is pulling the submission and will resubmit it with more data, and the firm is "re-evaluating" a similar FDA application. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|